成人难治性与超难治性癫痫持续状态的电休克治疗:范围综述
本范围综述检索Ovid MEDLINE和Scopus自建库至2024年2月的文献,纳入5项回顾性病例系列、共28例接受电休克治疗(ECT)的成人难治性(RSE)或超难治性癫痫持续状态(SRSE)患者。ECT在癫痫持续状态发生后3–70天(平均20天)内实施,每例平均疗程1–12次,剂量为固定或滴定。28例中20例(71%)临床改善,仅2例(7%)癫痫完全停止;11例(39%)死亡,死因与ECT无直接关系;4例(14%)报告记忆、注意力或认知障碍等不良反应。作者结论为现有证据等级低,临床决策应个体化,需前瞻性对照研究明确疗效、安全性和最佳方案。
要点
- 28例成人RSE/SRSE接受ECT,20例(71%)临床改善,但仅2例(7%)癫痫完全停止。
- ECT在癫痫持续状态发生后3–70天(平均20天)内实施,每例平均1–12次疗程,剂量固定或滴定。
- 11例(39%)死亡,死因与ECT无直接关系;4例(14%)出现记忆、注意力或认知障碍等不良反应。
- 证据为牛津证据等级4级、GRADE低级别,缺乏对照,临床改善可能存在过度报告。
- 作者认为 deciding ECT appropriateness 应结合个体临床背景,需前瞻性对照研究明确疗效、安全性和最佳方案。
适用人群与场景
- 成人难治性癫痫持续状态(RSE)或超难治性癫痫持续状态(SRSE)患者。
处置流程与药物剂量
- ECT在癫痫持续状态发生后3–70天(平均20天)内实施,每例平均疗程1–12次,剂量为固定或滴定。
研究设计与关键结果
- 5项回顾性病例系列,共28例成人RSE/SRSE患者接受ECT。
- ECT在癫痫持续状态发生后3–70天(平均20天)内实施,每例平均疗程1–12次,剂量固定或滴定。
- 28例中20例(71%)临床改善,2例(7%)癫痫完全停止。
- 11例(39%)死亡,死因与ECT无直接关系;4例(14%)报告记忆、注意力或认知障碍等不良反应。
证据类型、等级与局限
- 证据类型:范围综述,纳入5项回顾性病例系列。
- 证据等级:牛津循证医学中心4级,GRADE低级别。
- 局限:缺乏对照,临床改善可能存在过度报告;需前瞻性对照研究明确疗效、安全性和最佳方案。
对床旁实践的改变
- 作者认为,鉴于现有证据的局限性,临床医生在决定ECT是否适当时应仔细考虑患者个体临床背景。
- 作者指出,需要前瞻性对照研究来阐明ECT在RSE/SRSE管理中的疗效、安全性和最佳方案。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Electroconvulsive therapy (ECT) has been suggested as a treatment option for refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE).
OBJECTIVE: The objective of this scoping review was to conduct an extensive literature review on the role of ECT as a treatment option for RSE and SRSE.
METHODS: We searched Ovid MEDLINE and Scopus for journal articles from database inception until February 2024. Articles were then selected based on predetermined inclusion and exclusion criteria.
RESULTS: We identified five retrospective case series with 28 adult patients receiving ECT for RSE or SRSE. ECT was administered within 3-70 days (mean 20 days) after the development of SE, and the mean number of ECT courses ranged from 1 to 12 sessions for each patient. ECT was administered in fixed or titrated doses. A total of 20 out of 28 patients (71%) showed clinical improvement, with two (7%) having complete cessation of seizures. It is essential to note that given the lack of control, there could be overreporting of clinical improvement in these studies. 11 patients (39%) were reported as deceased due to causes that were not directly related to ECT treatment. Four patients (14%) reported adverse effects of ECT, including memory, concentration, and/or cognitive impairment.
CONCLUSIONS: There are level-4 Oxford Centre for Evidence-Based Medicine evidence and low-level Grading of Recommendations Assessment Development and Education evidence that suggest ECT as a treatment option for RSE and SRSE. In light of the limitations of the existing evidence, clinicians should carefully consider individual patients' clinical contexts when deciding on the appropriateness of ECT as a treatment option. Further research, including prospective studies with controlled designs, is needed to elucidate the efficacy, safety, and optimal regime of ECT in the management of RSE and SRSE.
参考来源
- Ong MJY, Lee VLL, Teo SL, et al. Electroconvulsive Therapy in Refractory and Super-Refractory Status Epilepticus in Adults: A Scoping Review. Neurocrit Care. 2024. PMID: 38769254. doi:10.1007/s12028-024-02003-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。